Related Experiment Video
Updated: Jun 9, 2026

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Efficacy and safety of ulcerative colitis therapies do not differ by age: A post hoc analysis of randomized
Emily C L Wong1, John K Marshall1, Christopher Ma2
1Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
Background:
Older adults with ulcerative colitis (UC) are often undertreated with advanced therapies due to safety concerns. We evaluated whether outcomes differ by age in randomized trials.
Methods:
Post hoc analysis of 2841 participants from 13 UC induction trials of biologics and JAK inhibitors compared efficacy (patient-reported outcomes 2 response/remission, clinical remission, endoscopic improvement) and safety between patients ≥60 years of age vs <60 years of age.
Results:
Efficacy and safety outcomes were similar across age groups, with minor therapy-specific variation. Hospitalization was numerically higher in older adults.
Conclusions:
Advanced therapies show comparable efficacy and safety in UC regardless of age.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Drug Dosing: Geriatric Patients
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Pharmacodynamics in Geriatric Patients: Effects of Age

